Category: Uncategorized

Committees of our Board In terms of the SEBI Listing Regulations and the provisions of the Companies Act, 2013, our Company has constituted the following Board-level committees: (a)       Audit Committee; (b)       Nomination and Remuneration Committee; (c)       Stakeholders’ Relationship Committee; (d)       Corporate Social Responsibility… Continue reading Committees of our Board

Healthvista India Limited – Familiarization Programme for Independent Director Adopted by the Board on 27th June 2022 PREAMBLE Regulation 25(7) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, inter alia requires the company to familiarize the independent directors with the Company, their… Continue reading Independent Director Familiarisation Programme

Introduction: The Nomination and Remuneration Policy (“Policy”) of Healthvista India Limited (“Company”) has been formulated pursuant to Section 178 of the Companies Act, 2013 read with the applicable rules made thereunder (collectively, the “Act”) and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), as amended from time to time. Objective and Purpose:… Continue reading Nomination and Remuneration Policy

INTRODUCTION Sub-regulation 1 of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (effective December 1, 2015) requires listed entity to formulate a policy on materiality of related party transactions and on dealing with related party transactions including clear threshold limits duly approved by the Board of Directors (the “Board”) at least… Continue reading POLICY ON RELATED PARTY TRANSACTIONS

HEALTHVISTA INDIA LIMITED – DIVIDEND DISTRIBUTION POLICY TITLE This Policy shall be called ‘Dividend Distribution Policy’. COMMENCEMENT This Policy shall come into force with effect from listing of the Company on Recognized Stock Exchange(s) OBJECTIVE This Policy is framed in accordance with the requirement under Regulation 43A of the Securities and Exchange Board of India… Continue reading DIVIDEND DISTRIBUTION POLICY

Mechanism for Redressal of Investor Grievances The agreement between the Registrar to the Offer, our Company and the Selling Shareholders provides for retention of records with the Registrar to the Offer for a period not less than eight years after completion of the Offer enable the investors to approach the Registrar to the Offer for… Continue reading Mechanism for Redressal of Investor Grievances

Investor Grievances Investors may contact our Company Secretary and Compliance Officer, the Book Running Lead Managers or the Registrar to the Offer in case of any pre-Offer or post-Offer related grievances, such as non-receipt of letters of Allotment, non-credit of Allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders or non-receipt of… Continue reading Investor Grievances

INVESTOR INFORMATION 1. FINANCIAL INFORMATION 2. OVERDUE TO MATERIAL CREDITORS 3. CORPORATE GOVERNANCE 4. POLICIES 5. INVESTOR GRIEVANCE REDRESSAL 6. INDUSTRY REPORT 7. SHAREHOLDING PATTERN 8. Contact details Name of Registrar – Link Intime India Private LimitedContact Person – Shanti GopalkrishnanTelephone and E-mail – Tel: +91 22 4918 6200E-mail: healthvista.ipo@linkintime.co.inSEBI Registration No.: INR000004058 CONTACT PERSON… Continue reading INVESTOR RELATIONS

Equipment Lease Agreement  THIS EQUIPMENT LEASE (“Lease”) is made and effective [Date], by and between Healthvista India Private Limited, a Company registered under the Companies Act, 1956 and having its registered office at No.69/B, 1st Cross, 1st Stage, Domlur Layout, Bangalore – 560071], (“Lessor”) and [Name of Lessee] (“Lessee“).  Lessor desires to lease to Lessee,… Continue reading Lease Agreement: Medical Equipment  

Download the annual return of the Company for 2019-20 Here Download the annual return of the Company for 2020-21 Here Download the annual return of the Company for 2021-22 Here Download the annual return of the Company for 2022-23 Here